Vendor qualification in multi-provider pain practices
Pain management and physical medicine groups usually have more than one prescribing or treating provider under a shared medical director, so vendor qualification tends to run through that medical director or a practice-wide compliance lead rather than an individual physician. The documentation request is similar to any other clinical supply decision: certificate of analysis, donor eligibility summary, and confirmation that registration and licensure records are available to inspect.
Precision Biologics treats every new account the same way regardless of practice size: verification first, documentation on request, no clinical recommendation attached to the sale.
- Certificate of analysis for the specific lot
- Donor eligibility summary
- Lot release record
- Registration and licensure documentation available on request
Spokane
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
90- Pain Medicine
- 24
- Physical Medicine & Rehabilitation
- 66
Receiving and inventory control for cold-chain products
Cryopreserved Wharton's jelly formats are shipped overnight on dry ice after storage at -80 degrees C, and lyophilized formats are shelf-stable once received. In a practice with multiple treatment rooms, the harder problem is usually internal: making sure the lot number that arrives at the front desk is the same lot number logged against the patient record where the product is eventually used. Building that intake step once, at receiving, avoids having to reconstruct it later.
Confirming scope and regulatory posture with counsel
Exosome products are not FDA-approved, and FDA has stated there are no FDA-approved exosome products on the market; they are generally regulated as biologic drugs. Whether a specific use of either product category fits a practice's regulatory posture is a decision for the practice's medical director and its own counsel, and Precision Biologics recommends practices confirm that position with the Washington medical board directly rather than relying on supplier materials alone.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Does Precision Biologics work with multi-provider pain practices in Spokane?+
Yes. Accounts can be set up at the practice level once an NPI is verified; a medical director or compliance lead can manage documentation requests for the group.
Are Bio Xsomes or other exosome products FDA-approved?+
No. FDA has stated there are no FDA-approved exosome products. Purchase and use decisions belong to the physician and their own regulatory counsel.
What should a Spokane pain practice ask for before ordering a lot?+
A certificate of analysis for that lot, a donor eligibility summary, and the lot release record; full characterization data is available to verified accounts on request.